However, long‐term use of l‐DOPA leads to a gradual loss of drug efficacy and side effects such as motor fluctuations and dyskinesia.[1] An attractive alternative to targeting only the dopamine receptors is to consider the network of G‐protein‐coupled receptors (GPCRs) in the basal ganglia controlling movement, which includes the A2A adenosine receptor.[12] A compound with the ability to interact with both the A2A adenosine receptor (A2AAR) and the D2 dopamine receptor (D2R) could delay progression of the disease and treat the symptoms. The gene discussed is DRD2; the disease is Dyskinesia.